- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04195958
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma (EDURO)
A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Rolling Hills Estates, California, United States, 90274
- Peninsula Research Associates
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
Florida
-
Pembroke Pines, Florida, United States, 33024
- Broward Research Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals & Clinics; Internal Medicine
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0934
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - Rochester
-
-
New York
-
New York, New York, United States, 10075
- Lenox Hill Hospital
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28277
- American Health Research Inc.
-
-
Ohio
-
Cleveland, Ohio, United States, 44016
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple Uni Medical Center; Pulmonary & Critical Care Medicine
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
- Spartanburg Medical Research
-
-
Washington
-
Seattle, Washington, United States, 98122
- Swedish Health Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physician-diagnosed asthma for at least 12 months prior to screening
- Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen
- Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period
- Able to safely complete incremental exercise tolerance at screening
- Pre-bronchodilator FEV1 of 40%-80% of predicted at screening
- Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry
- On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (≥)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for ≥3 months prior to screening
- Uncontrolled asthma during the screening period, defined as an ACQ-5 ≥0.75 score
- Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug.
Exclusion Criteria:
- Known history of anaphylaxis/hypersensitivity to omalizumab
- Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening
- Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening
- Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period
- Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period
- Isolated diagnosis of exercise induced asthma without chronic symptoms
- History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma
- Current malignancy or history of malignancy within 5 years prior to screening
- Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions
- Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening
- Current smoker or past smoker with >10 pack years
- Known HIV infection at screening
- Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening
- Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening
- Active tuberculosis requiring treatment within 12 months prior to screening
- History of alcohol, drug, or chemical abuse within 6 months of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omalizumab
|
Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks.
The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline at Week 24 in Endurance Time (Minutes) During Cardiopulmonary Exercise Testing (CPET) at a Constant Work Rate (CWR)
Time Frame: From Baseline to Week 24
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline at Week 24 in Physical Activity (Minutes/Day) as Assessed by a Wearable Physical Activity and Sleep Monitor
Time Frame: From Baseline to Week 24
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 24
|
Change From Baseline at Week 24 in Dynamic Hyperinflation at Isotime, as Measured by Inspiratory Capacity During CPET at a CWR
Time Frame: From Baseline to Week 24
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 24
|
Change From Baseline at Week 24 in Sleep Efficiency as Assessed by a Wearable Physical Activity and Sleep Monitor
Time Frame: From Baseline to Week 24
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 24
|
Percentage of Participants With Adverse Events
Time Frame: From Baseline to Week 28
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 28
|
Percentage of Participants With Serious Adverse Events
Time Frame: From Baseline to Week 28
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 28
|
Percentage of Participants With Adverse Events Leading to Discontinuation of Omalizumab
Time Frame: From Baseline to Week 24
|
This study was terminated by the Sponsor.
Only 3 participants were enrolled in this study.
Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
|
From Baseline to Week 24
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML41615
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate-to-severe Allergic Asthma
-
The First Affiliated Hospital with Nanjing Medical...RecruitingModerate to Severe Allergic AsthmaChina
-
Cytos Biotechnology AGTerminatedModerate to Severe Allergic AsthmaUnited States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine
-
CinnagenCompletedAllergic Asthma | Uncontrolled Moderate to SevereIran, Islamic Republic of
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationCompletedMild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital RhytidsUnited States
-
Aqpha Medical B.V.Not yet recruitingModerate to Severe Nasolabial Fold
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Galderma R&DCompletedModerate to Severe Glabellar LinesChina
-
EuBiologics Co.,LtdCompletedModerate to Severe Glabellar LinesKorea, Republic of
-
AllerganCompletedModerate to Severe Nasolabial FoldsGermany, Netherlands
Clinical Trials on Omalizumab
-
Massachusetts General HospitalGenentech, Inc.CompletedNasal Polyps | Chronic RhinosinusitisUnited States
-
Medical University of SilesiaCentrum Medyczne Andrzej BożekNot yet recruitingAsthma, Allergic
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
NovartisGenentech, Inc.; TanoxCompletedAsthmaUnited States, Argentina, Germany
-
Bernstein Clinical Research CenterWithdrawn
-
The University Clinic of Pulmonary and Allergic...UnknownAllergy | Immunotherapy | Omalizumab | Bee VenomSlovenia
-
Stanford UniversityCompletedAtopic DermatitisUnited States
-
Boston Children's HospitalStanford UniversityCompleted
-
IRCCS Policlinico S. MatteoCompletedInterstitial Cystitis | Painful Bladder SyndromeItaly